# WIA-AUG-010 PHASE 1 — Data Format Specification **Standard:** WIA-AUG-010 **Phase:** 1 — Data Format **Version:** 1.0 **Status:** Stable **Source:** synthesized from the original `PHASE-1-DATA-FORMAT.md` (quarter 1 of 4) --- # WIA-AUG-010: Artificial Organ Specification v1.0 > **Standard ID:** WIA-AUG-010 > **Version:** 1.0.0 > **Published:** 2025-12-27 > **Status:** Active > **Authors:** WIA Human Augmentation Working Group --- ## Table of Contents 1. [Introduction](#1-introduction) 2. [Organ Classification Taxonomy](#2-organ-classification-taxonomy) 3. [Technology Type Framework](#3-technology-type-framework) 4. [Biocompatibility Assessment](#4-biocompatibility-assessment) 5. [Function Monitoring System](#5-function-monitoring-system) 6. [Rejection Detection Protocol](#6-rejection-detection-protocol) 7. [Performance Optimization](#7-performance-optimization) 8. [Power and Energy Systems](#8-power-and-energy-systems) 9. [Maintenance and Service Scheduling](#9-maintenance-and-service-scheduling) 10. [Failsafe and Emergency Protocols](#10-failsafe-and-emergency-protocols) 11. [Interoperability Standards](#11-interoperability-standards) 12. [Implementation Guidelines](#12-implementation-guidelines) 13. [References](#13-references) --- ## 1. Introduction ### 1.1 Purpose This specification defines a comprehensive framework for artificial organ technologies, providing standardized classification systems, biocompatibility protocols, function monitoring, rejection detection, and interoperability guidelines for artificial organ devices and systems. ### 1.2 Scope The standard covers: - Taxonomy and classification of artificial organ types - Technology category frameworks (mechanical, bioartificial, bioprinted, xenotransplant) - Biocompatibility assessment protocols - Real-time function monitoring systems - Rejection detection and early warning - Performance optimization algorithms - Power and energy system requirements - Maintenance scheduling and predictive service - Emergency failsafe mechanisms - Interoperability and data exchange standards ### 1.3 Philosophy **弘益人間 (Benefit All Humanity)** - Artificial organ technology should restore and enhance organ function while maintaining patient safety, quality of life, and equitable access. This specification ensures that artificial organs are developed with standardized frameworks that promote biocompatibility, reliability, and ethical deployment. ### 1.4 Terminology - **Artificial Organ**: Device or biological construct that replaces or augments natural organ function - **Biocompatibility**: Degree of compatibility between artificial organ and host tissue - **Rejection**: Immune system response against artificial organ or its components - **Function Metrics**: Quantifiable measurements of organ performance - **Failsafe**: Backup system activated during primary system failure - **Xenotransplant**: Transplantation of cells, tissues, or organs from non-human species --- ## 2. Organ Classification Taxonomy ### 2.1 Primary Organ Types Artificial organs are classified into eight primary types: | Type | Code | Primary Function | Critical Metrics | |------|------|------------------|------------------| | Heart | HEART | Cardiac output, circulation | Flow rate, pressure, rhythm | | Kidney | KIDNEY | Filtration, fluid balance | GFR, electrolytes, waste removal | | Liver | LIVER | Metabolism, detoxification | Enzyme synthesis, waste processing | | Lung | LUNG | Gas exchange | O2/CO2 transfer, ventilation | | Pancreas | PANCREAS | Endocrine, exocrine | Insulin, glucose control, enzymes | | Bladder | BLADDER | Urinary storage | Capacity, pressure, continence | | Intestine | INTESTINE | Digestion, absorption | Nutrient uptake, motility | | Skin | SKIN | Barrier, sensation | Coverage, healing, sensory function | ### 2.2 Classification Algorithm ```typescript interface OrganInput { primaryFunction: OrganType; technologyApproach: TechnologyType; targetPerformance: number; // % of natural organ invasiveness: number; // 1-10 reversibility: boolean; } function classifyOrgan(input: OrganInput): OrganClassification { const type = input.primaryFunction; const technology = input.technologyApproach; const performanceLevel = determinePerformanceLevel(input.targetPerformance); const safetyClass = calculateSafetyClass(input.invasiveness, technology); return { type, technology, performanceLevel, safetyClass, reversible: input.reversibility }; } ``` ### 2.3 Organ-Specific Requirements #### 2.3.1 Heart (Cardiac) - **Flow Rate**: 4-6 L/min at rest, 20-25 L/min peak - **Pressure**: Systolic 120 mmHg, Diastolic 80 mmHg - **Rhythm**: 60-100 bpm, regular - **Efficiency**: >75% mechanical efficiency - **Durability**: >5 years continuous operation #### 2.3.2 Kidney (Renal) - **GFR**: >90 ml/min/1.73m² optimal - **Filtration**: Creatinine clearance >80 ml/min - **Electrolyte Balance**: Na⁺, K⁺, Ca²⁺, PO₄³⁻ regulation - **Waste Removal**: Urea, creatinine, toxins - **Durability**: >3 years with maintenance #### 2.3.3 Liver (Hepatic) - **Detoxification**: Ammonia → urea conversion - **Synthesis**: Albumin, clotting factors, glucose - **Metabolism**: Drug metabolism, lipid processing - **Storage**: Glycogen, vitamins, minerals - **Regeneration**: Self-repair capability (bioartificial) #### 2.3.4 Lung (Pulmonary) - **Gas Exchange**: O₂ uptake >250 ml/min, CO₂ removal >200 ml/min - **Ventilation**: Tidal volume 500 ml, RR 12-20/min - **Compliance**: Adequate chest wall interaction - **Resistance**: Minimal airway resistance - **Durability**: >2 years continuous operation #### 2.3.5 Pancreas (Endocrine/Exocrine) - **Insulin Production**: Glucose-responsive 40-50 units/day - **Glucose Control**: Maintain 70-140 mg/dL - **Enzyme Production**: Amylase, lipase, proteases - **Response Time**: <15 minutes to glucose changes - **Biocompatibility**: High, minimal immune response #### 2.3.6 Bladder (Urinary) - **Capacity**: 300-500 ml - **Continence**: >95% leak-free - **Pressure Management**: <40 cmH₂O at capacity - **Sensation**: Fullness awareness (if neural integrated) - **Durability**: >5 years #### 2.3.7 Intestine (Digestive) - **Absorption**: >70% nutrient uptake - **Motility**: Peristaltic movement - **Barrier Function**: Prevent bacterial translocation - **Surface Area**: Adequate villi/microvilli - **Durability**: >3 years with maintenance #### 2.3.8 Skin (Integumentary) - **Coverage**: Complete wound closure - **Barrier Function**: Prevent infection, water loss - **Sensation**: Touch, temperature, pain (if integrated) - **Appearance**: Cosmetically acceptable - **Healing**: Integration with surrounding tissue --- ## 3. Technology Type Framework ### 3.1 Technology Categories Five primary technology approaches for artificial organs: | Type | Code | Mechanism | Examples | Advantages | Challenges | |------|------|-----------|----------|------------|------------| | Mechanical | MECH | Electromechanical devices | Total artificial heart, dialysis | Reliable, durable | Biocompatibility, power | | Bioartificial | BIOART | Living cells + scaffold | BAL, bioartificial kidney | Natural function | Cell viability, scaling | | 3D Bioprinted | BIOPRINT | Printed tissue constructs | Skin, bladder, vascular | Patient-specific | Complexity, vascularization | | Xenotransplant | XENO | Modified animal organs | Pig heart, kidney | Availability, complete | Rejection, disease risk | | Hybrid | HYBRID | Combined approaches | Bio-mechanical devices | Optimized performance | Integration complexity | ### 3.2 Technology Selection Criteria ``` Technology Score = (Function_Match × 0.30) + (Biocompatibility × 0.25) + (Durability × 0.20) + (Availability × 0.15) + (Cost_Effectiveness × 0.10) where each factor is scored 0-1 Recommendations: Score ≥ 0.80: Highly Recommended Score 0.60-0.79: Recommended with conditions Score 0.40-0.59: Alternative approaches suggested Score < 0.40: Not recommended ``` ### 3.3 Mechanical Systems #### 3.3.1 Design Requirements - **Materials**: Titanium, medical-grade polymers, ceramics - **Surface Treatment**: Anti-thrombogenic coatings - **Pumping Mechanism**: Continuous flow or pulsatile - **Wear Resistance**: >5 million cycles without degradation - **Noise Level**: <40 dB #### 3.3.2 Control Systems - **Sensors**: Pressure, flow, temperature - **Feedback**: Real-time performance adjustment - **Safety Limits**: Automatic shutoff on fault detection - **Power Management**: Battery backup, low-power modes ### 3.4 Bioartificial Systems #### 3.4.1 Cell Requirements - **Cell Type**: Primary cells, stem cell-derived, immortalized lines - **Viability**: >90% at implantation, >70% at 1 year - **Function**: Organ-specific metabolic activity - **Immunoisolation**: Encapsulation or genetic modification - **Nutrient Supply**: Vascularization or perfusion system #### 3.4.2 Scaffold Requirements - **Material**: Biodegradable (PCL, PLGA) or permanent (hydrogels) - **Architecture**: Porous, 3D structure mimicking natural ECM - **Mechanical Strength**: Adequate for organ function - **Biocompatibility**: ISO 10993 compliant - **Degradation**: Controlled rate matching tissue ingrowth ### 3.5 3D Bioprinted Systems #### 3.5.1 Bioprinting Requirements - **Resolution**: 50-200 μm for cell placement - **Bioink**: Cell-laden hydrogels with >85% cell viability - **Vascularization**: Integrated blood vessel network - **Maturation**: In vitro culture before implantation - **Quality Control**: Imaging, function testing, sterility #### 3.5.2 Tissue Engineering - **Cell Density**: Organ-appropriate cell concentration - **ECM Components**: Collagen, fibronectin, laminin - **Growth Factors**: VEGF, bFGF for vascularization - **Mechanical Stimulation**: Bioreactor conditioning - **Integration**: Host tissue infiltration ### 3.6 Xenotransplant Systems #### 3.6.1 Genetic Modification - **Human Transgenes**: HLA, CD55, CD59 for immune protection - **Knockout Genes**: α-Gal, CMAH, Neu5Gc for antigen reduction - **PERV Inactivation**: Eliminate porcine endogenous retrovirus - **Quality Assurance**: Genetic stability verification #### 3.6.2 Immunosuppression - **Protocol**: Multi-drug regimen (calcineurin inhibitors, corticosteroids) - **Monitoring**: Drug levels, immune markers - **Infection Prevention**: Prophylactic antimicrobials - **Long-term**: Tolerance induction strategies --- ## 4. Biocompatibility Assessment ### 4.1 Biocompatibility Framework ``` Biocompatibility Score = (Tissue_Integration × 0.30) + (Immune_Response × 0.25) + (Material_Safety × 0.25) + (Functional_Stability × 0.20) where: - Tissue_Integration: Capsule thickness, vascularization (0-1) - Immune_Response: Inflammation markers, cell infiltration (0-1, 1=minimal) - Material_Safety: Toxicity, degradation products (0-1) - Functional_Stability: Performance over time (0-1) ``` ### 4.2 Tissue Integration Assessment ```typescript interface TissueIntegration { capsuleThickness: number; // mm (thinner is better) vascularization: number; // vessels/mm² cellInfiltration: number; // cells/mm² (appropriate type) fibrosis: number; // 0-4 score (0=none) adhesions: number; // 0-4 score (0=none) } function assessTissueIntegration(data: TissueIntegration): number { const capsuleScore = capsuleNormalize(data.capsuleThickness); // <1mm = good const vascScore = vascularizationNormalize(data.vascularization); const fibrosisScore = 1 - (data.fibrosis / 4); const adhesionScore = 1 - (data.adhesions / 4); return (capsuleScore + vascScore + fibrosisScore + adhesionScore) / 4; } ``` ### 4.3 Immune Response Monitoring #### 4.3.1 Inflammation Markers - **CRP (C-Reactive Protein)**: <10 mg/L normal, 10-100 moderate, >100 high - **ESR (Erythrocyte Sedimentation Rate)**: <20 mm/h normal - **WBC (White Blood Cell Count)**: 4,000-11,000/μL normal - **Cytokines**: IL-6, TNF-α, IL-1β levels - **Complement**: C3, C4 activation #### 4.3.2 Antibody Surveillance - **Anti-HLA Antibodies**: Donor-specific antibodies (DSA) - **Panel Reactive Antibodies (PRA)**: % reactivity - **IgG/IgM**: Immunoglobulin levels - **Crossmatch**: T-cell, B-cell crossmatch tests - **Monitoring Frequency**: Weekly (month 1), monthly (months 2-12), quarterly thereafter ### 4.4 Material Safety Testing #### 4.4.1 ISO 10993 Compliance - **Cytotoxicity**: In vitro cell viability >70% - **Sensitization**: Guinea pig maximization test - **Irritation**: Rabbit dermal/ocular testing - **Systemic Toxicity**: Acute and subchronic studies - **Genotoxicity**: Ames test, chromosomal aberration - **Implantation**: Subcutaneous implant studies (4-52 weeks) - **Hemocompatibility**: Hemolysis, thrombogenicity, complement #### 4.4.2 Degradation Product Analysis - **Leachables**: Chemical analysis of released substances - **Particulates**: Size, composition, toxicity - **Metal Ions**: Titanium, cobalt, chromium levels (if applicable) - **Polymer Breakdown**: Monomer, oligomer detection - **Biological Products**: Cell debris, proteins --- ## Annex E — Implementation Notes for PHASE-1-DATA-FORMAT The following implementation notes document field experience from pilot deployments and are non-normative. They are republished here so that early adopters can read them in context with the rest of PHASE-1-DATA-FORMAT. - **Operational scope** — implementations SHOULD declare their operational scope (single-tenant, multi-tenant, federated) in the OpenAPI document so that downstream auditors can score the deployment against the correct conformance tier in Annex A. - **Schema evolution** — additive changes (new optional fields, new error codes) are non-breaking; renaming or removing fields, even in error payloads, MUST trigger a minor version bump. - **Audit retention** — a 7-year retention window is sufficient to satisfy ISO/IEC 17065:2012 audit expectations in most jurisdictions; some regulators require longer retention, in which case the deployment policy MUST extend the retention window rather than relying on this PHASE's defaults. - **Time synchronization** — sub-second deadlines depend on synchronized clocks. NTPv4 with stratum-2 servers is sufficient for most deadlines expressed in this PHASE; PTP is recommended for sites that require deterministic interlocks. - **Error budget reporting** — implementations SHOULD publish a monthly error-budget summary (latency p95, error rate, violation hours) in the format defined by the WIA reporting profile to facilitate cross-vendor comparison without exposing tenant-specific data. These notes are not requirements; they are a reference for field teams mapping their existing operations onto WIA conformance. ## Annex F — Adoption Roadmap The adoption roadmap for this PHASE document is non-normative and is intended to set expectations for early implementers about the relative stability of each section. - **Stable** (sections marked normative with `MUST` / `MUST NOT`) — semantic versioning applies; breaking changes require a major version bump and at minimum 90 days of overlap with the prior major version on all WIA-published reference implementations. - **Provisional** (sections in this Annex and Annex D) — items are tracked openly and may be promoted to normative status without a major version bump if community feedback supports promotion. - **Reference** (test vectors, simulator behaviour, the reference TypeScript SDK) — versioned independently of this document so that mistakes in reference material can be corrected without amending the published PHASE document. Implementers SHOULD subscribe to the WIA Standards GitHub release notifications to track promotions between these tiers. Comments on the roadmap are accepted via the GitHub issues tracker on the WIA-Official organization. The roadmap is reviewed at every minor version of this PHASE document, and the review outcomes are recorded in the version-history table at the start of the document. ## Annex G — Test Vectors and Conformance Evidence This annex describes how implementations capture and publish conformance evidence for PHASE-1-DATA-FORMAT. The procedure is non-normative; it standardizes the shape of evidence so that auditors and downstream integrators can compare implementations without re-running the full test matrix. - **Test vectors** — every normative requirement in this PHASE has at least one positive vector and one negative vector under `tests/phase-vectors/phase-1-data-format/`. Implementations claiming conformance MUST run all vectors in CI and publish the resulting pass/fail matrix in their compliance package. - **Evidence package** — the compliance package is a tarball containing the SBOM (CycloneDX 1.5 or SPDX 2.3), the OpenAPI document, the test vector matrix, and a signed manifest. Signatures use Sigstore (DSSE envelope, Rekor transparency log entry) so that downstream consumers can verify provenance without trusting a private CA. - **Quarterly recheck** — implementations re-publish the evidence package every quarter even if no source change occurred, so that consumers can detect environmental drift (compiler updates, dependency updates, OS updates) without polling vendor changelogs. - **Cross-vendor crosswalk** — the WIA Standards working group maintains a crosswalk that maps each vector to the equivalent assertion in adjacent industry programs (where one exists), so an implementer that already certifies under one program can show conformance to PHASE-1-DATA-FORMAT with reduced incremental effort. - **Negative-result reporting** — vendors MUST report negative results with the same fidelity as positive ones. A test that is skipped without recorded justification is treated by auditors as a failure. These conventions are intended to make conformance evidence portable and machine-readable so that adoption of PHASE-1-DATA-FORMAT does not require bespoke auditor tooling. ## Annex H — Versioning and Deprecation Policy This annex codifies the versioning and deprecation policy for PHASE-1-DATA-FORMAT. It is non-normative; the rules below describe the policy that the WIA Standards working group commits to when amending this PHASE document. - **Semantic versioning** — major / minor / patch components follow Semantic Versioning 2.0.0 (https://semver.org/spec/v2.0.0.html). Major bump indicates a backwards-incompatible change to a normative requirement; minor bump indicates new normative requirements that do not break existing implementations; patch bump indicates editorial changes only (clarifications, typo fixes, formatting). - **Deprecation window** — when a normative requirement is removed or altered in a backwards-incompatible way, the prior major version is maintained in parallel for at least 180 days. During the parallel window, both major versions are marked Stable in the WIA Standards registry and either may be cited as "WIA-conformant". - **Sunset notification** — deprecated major versions enter a 12-month sunset window during which the WIA registry marks the version as Deprecated. The deprecation entry includes a migration note pointing to the replacement requirement(s) and an explanation of why the change was made. - **Editorial errata** — patch-level errata are issued without a deprecation window because they do not change normative behaviour. Errata are tracked in a public errata register and each entry is signed by the WIA Standards working group chair. - **Implementation changelog mapping** — implementations SHOULD publish a changelog mapping each PHASE version they support to the specific build, container digest, or SDK version that satisfies the version. This allows downstream auditors to verify version conformance without re-running the entire test matrix on every release. The policy is reviewed at the same cadence as the PHASE document and any changes to the policy itself are tracked in the version-history table at the start of the document. ## Annex I — Interoperability Profiles This annex describes how implementations declare interoperability profiles for PHASE-1-DATA-FORMAT. The profile mechanism is non-normative and exists so that deployments of varying scope (single tenant, regional cluster, federated network) can advertise the subset of normative requirements they satisfy without misrepresenting partial conformance as full conformance. - **Profile manifest** — every implementation publishes a profile manifest in JSON. The manifest enumerates the normative requirement IDs from this PHASE that are satisfied (`status: "supported"`), partially satisfied (`status: "partial"`, with a reason field), or excluded (`status: "excluded"`, with a justification). The manifest is signed using the same Sigstore key used for the SBOM in Annex G. - **Federation profile** — federated deployments publish an aggregated manifest summarizing the union and intersection of member-implementation profiles. The aggregated manifest is consumed by directory services so that callers can route a request to the least common denominator profile required for an interaction. - **Backwards-profile compatibility** — when a deployment migrates from one profile to a wider profile, the prior profile manifest remains valid and signed for the deprecation window defined in Annex H. This preserves audit traceability for auditors evaluating long-term interoperability. - **Profile registry** — the WIA Standards working group maintains a public registry of named profiles. Common deployment shapes (e.g., "Edge-only", "Federated-with-replay") are added to the registry by consensus. Registry entries are immutable; new shapes are added under new names rather than amending existing entries. - **Profile versioning** — profile names are versioned with the same Semantic Versioning rules described in Annex H. A deployment that advertises `WIA-P1-DATA-FORMAT-Edge-only/2` is asserting conformance with the second major version of the named profile, not the second deployment of an unversioned profile. The profile mechanism is intentionally lightweight; it is meant to make real deployment shapes visible without forcing every deployment to satisfy every normative requirement. ## Annex J — Reference Implementation Topology The reference implementation topology described in this annex is non-normative; it documents the deployment shape that the WIA Standards working group used to validate the test vectors in Annex G and is intended as a starting point, not a recommendation against alternative topologies. - **Single-tenant edge** — one runtime per organization, no shared state. Used for early-pilot deployments where conformance evidence is published manually. Sufficient for PHASE-1-DATA-FORMAT validation when the organization signs the manifest itself. - **Multi-tenant gateway** — one shared runtime serves multiple tenants via header-based isolation. Typically backed by a rate-limited gateway (Envoy or NGINX) and a shared OAuth 2.1 identity provider. The manifest is per-tenant; the runtime publishes a federation manifest that aggregates tenant manifests. - **Federated mesh** — multiple runtimes peer to one another and publish their manifests to a directory service. Each peer signs its own manifest; the directory service signs the aggregated index. This is the topology used by cross-organization deployments that need to compose conformance. - **Air-gapped batch** — no network connection between the runtime and the directory service. The runtime emits a signed evidence package on each batch and the operator transports the package via out-of-band channels. This is the topology used by regulators that prohibit live connectivity from sensitive environments. Implementations declare their topology in the manifest (see Annex I). A topology change MUST be reflected in a new manifest signature; the prior topology's manifest remains valid for the deprecation window described in Annex H to preserve audit traceability.